Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
Search insider filingsAll Congress filings
MORE TOOLS
WatchlistGold IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeSearch insider filingsAll Congress filings
More research tools
ExploreGold IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
Back to Home
A

AGMB

Nasdaq

AgomAb Therapeutics NV

Latest disclosureOctober 7, 2026
Insider score Why 87?
87/ 100
Qualifying buys · 30d
$266.67K

7 purchases · 0 sales

Price by TradingViewDelayed quote from TradingView, for viewing only. It does not power Whale Atlas scores or alerts. If the quote does not load, open the TradingView link.

Insider transactions 9

Limited filing history
All9Buying7Selling0Other2
Filters

Last 30 daysInsiders bought $266.67K · 3 buyers, led by Tim Jasper Knotnerus (CEO) with $94.38K. No qualifying insider sales.

2 of 9 trades · September 11, 2026 – October 6, 2026Incomplete history: this shows the filings imported so far, not every filing ever made. Dates are trade dates. Filters affect this table only.
Award disclosed

Marino Garcia

Director

Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 11, 2026Filed September 15, 2026SEC filing
Award disclosed

Naimish Patel

Director

Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 11, 2026Filed September 15, 2026SEC filing
Reporting insiderSecurity / transactionAmount / priceValueTraded / disclosedSource
DirectorStock Option (Right to Buy)Grant or awardDerivative units57,482Award · no purchase priceNon-cash awardSep 11Filed Sep 15 · 4d laterSEC filing
DirectorStock Option (Right to Buy)Grant or awardDerivative units56,328Award · no purchase priceNon-cash awardSep 11Filed Sep 15 · 4d laterSEC filing

Congress transactions 0

All Congress filings
No disclosed congressional trades for AGMB in the imported filings.

This reflects the filings imported so far, not a complete trading history.

Explore furtherTechnical lab Company financials Test a strategy Compare company

Why this buying score?

Qualifying common-equity purchase value

$266,670 of common-equity purchase value after transaction-age decay across 180 days.

+12 pts

Distinct buying groups

3 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.

+20 pts

CEO purchase

Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.

+15 pts

CFO purchase

Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.

+10 pts

Insider buying cluster

3 buying groups inside 30 transaction-date days, public by the snapshot cutoff.

+15 pts

Repeated purchases

A reporting-owner group bought on at least two distinct dates within the cluster window.

+5 pts

Material reported holdings increase

At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.

+10 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage
Source
SEC EDGAR · Form 4
Issuer CIK
0002020932
Latest public acceptance
Oct 7, 2026, 12:57 PM UTC
Score calculated
Oct 7, 2026, 01:02 PM UTC
Parser
form4-parser-1.5
Classifier
form4-classifier-1.1
Scoring methodology
insider-experimental-1.1
Availability
Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.